Protein-Tyrosine Kinases (Tyrosine Kinase)

6153  relevant articles (269 outcomes, 595 trials/studies) found for this Bio-Agent

Tyrosine Kinase; Protein-Tyrosine Kinase; Kinase, Tyrosine; Tyrosine Protein Kinases; Tyrosine-Specific Protein Kinases; Tyrosylprotein Kinase; Kinase, Protein-Tyrosine; Kinase, Tyrosine Protein; Kinase, Tyrosine-Specific Protein; Kinase, Tyrosylprotein; Kinases, Protein-Tyrosine; Kinases, Tyrosine Protein; Kinases, Tyrosine-Specific Protein; Protein Kinase, Tyrosine-Specific; Protein Kinases, Tyrosine; Protein Kinases, Tyrosine-Specific; Protein Tyrosine Kinase; Protein Tyrosine Kinases; Tyrosine Specific Protein Kinase; Tyrosine Specific Protein Kinases; Tyrosine Protein Kinase; Tyrosine-Specific Protein Kinase; ATP:protein-tyrosine O-phosphotransferase

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Griffin, James D: 11 articles (05/2008 - 05/2002)
2.	Gilliland, D Gary: 10 articles (10/2005 - 06/2002)
3.	Normanno, Nicola: 7 articles (11/2008 - 02/2004)
4.	Kantarjian, Hagop: 7 articles (09/2008 - 03/2003)
5.	Fidler, Isaiah J: 7 articles (05/2008 - 11/2002)
6.	Herbst, Roy S: 7 articles (10/2007 - 09/2002)
7.	Shibuya, Masabumi: 6 articles (03/2008 - 08/2003)
8.	Hoelzer, Dieter: 6 articles (11/2004 - 01/2002)
9.	Ottmann, Oliver G: 6 articles (11/2004 - 01/2002)
10.	Cortes, Jorge: 5 articles (09/2008 - 11/2006)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2006 - "Histologic diagnosis of these tumors are important considering the efficacy of tyrosine kinase inhibitor therapy after surgery in such cases." 07/01/2003 - "It is important to distinguish GISTs from other mesenchymal tumors of the GI tract because of differences in natural history, as well as the efficacy of treatments targeting the GIST tyrosine kinase." 09/01/1999 - "Role of neurotrophin-trk interactions in oncology: the anti-tumor efficacy of potent and selective trk tyrosine kinase inhibitors in pre-clinical tumor models." 09/01/1996 - "Compared with control specimens (mean PTK = 20.5), tyrosine kinase activity was significantly greater in invasive primary cancers (mean PTK = 298.1; p = 0.0008), and nodal/metastatic specimens (mean PTK = 491.5; p = 0.0009). " 09/15/2007 - "CONCLUSIONS: The presence of a subgroup of NSCLCs with an activated autocrine loop may help to explain the mechanisms that lead to the relative ineffectiveness of the EGFR tyrosine kinase inhibitor and may support new clinical trials to define whether the subgroup of patients with these tumors reasonably may benefit from higher doses of such inhibitors or from the simultaneous inhibition of EGFR downstream signaling targets." Order ALL the reference details at left...
2.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 04/01/2009 - "Tyrosine kinase inhibitors (TKIs) have dramatically improved the treatment of chronic myeloid leukemia (CML). " 09/01/2000 - "Tyrosine kinase inhibitors: a cure for chronic myeloid leukemia?" 08/01/2004 - "In a previous study, we reported that protein tyrosine kinase (PTK) inhibitors modulate the radiation responses in the human chronic myelogenous leukemia (CML) cell line K562. " 02/01/2002 - "OBJECTIVE: To study the effects of anti-ABL tyrosine kinase intrabody on the growth of human chronic myelogenous leukemia (CML) cells in nude mice. " 07/01/2001 - "Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors." Order ALL the reference details at left...
3.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 08/01/2009 - "The EGFR has been targeted through the development of selective tyrosine kinase inhibitors (TKIs) that have proven effective in a subset of non-small cell lung cancer (NSCLC) patients, many bearing gain-of-function EGFR mutations or egfr gene amplification. " 06/01/2009 - "Early clinical studies of tyrosine kinase inhibitors (TKIs) that target the EGFR in patients with advanced non-small-cell lung cancer (NSCLC) showed that some patients experienced rapid, durable, complete or partial responses. " 08/01/2007 - "In vitro studies have shown that EGFR tyrosine kinase inhibitors (TKIs) greatly inhibit cellular growth and induced apoptosis in the ATC cell lines, while somatic mutations in the tyrosine kinase domain or an increased gene copy number are associated with increased sensitivity to TKIs in non-small cell lung cancer. " 09/01/2004 - "To date, results of phase II or III trials of tyrosine kinase inhibitors have yielded mixed results, with moderate activity but no increase in survival reported in patients with advanced non-small cell lung cancer. " 11/12/2009 - "Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer." Order ALL the reference details at left...
4.	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 06/01/2003 - "Activated receptor-associated tyrosine kinase c-kit, mutated in most gastrointestinal stromal tumors, has proven a clinically effective target for enzyme inhibition. " 01/01/2008 - "BACKGROUND: Tyrosine kinase inhibitors have been shown to have marked clinical efficacy in patients with unresectable or metastatic gastrointestinal stromal tumors (GIST). " 02/01/2003 - "Recent studies have shown that cells in gastrointestinal stromal tumors express a growth factor receptor with tyrosine kinase activity termed c-kit. " 11/01/2009 - "BACKGROUND: Gastrointestinal stromal tumors (GISTs) harbor gain-of-function mutations of the c-kit tyrosine kinase receptor. " 06/25/2009 - "Most of human gastrointestinal stromal tumors (GIST) are driven by activating mutations in the proto-oncogene KIT, a tyrosine kinase receptor. " Order ALL the reference details at left...
5.	Breast Neoplasms (Breast Cancer) 01/17/1996 - "Tyrosine kinase inhibitors might, therefore, be useful for the treatment of breast cancer." 03/11/2008 - "This minireview discusses the role of one selected ABC-transporter family member, the breast cancer resistance protein (BCRP/ABCG2), in the (pre)clinical efficacy of novel experimental anticancer drugs, in particular tyrosine kinase inhibitors." 11/01/2006 - "These findings suggest that the EGFR intron 1 polymorphism may influence response to treatment with tyrosine kinase inhibitors in breast cancer patients and further studies are warranted." 01/01/2005 - "Results of phase II clinical trials of EGFR tyrosine kinase inhibitors (TKIs) have shown that these compounds have little activity in breast cancer patients when used as single agents. " 12/17/2003 - "CONCLUSION: This study appears to provide the preclinical rationale for the development of these EGFR tyrosine kinase inhibitors for the prevention of human breast cancer." Order ALL the reference details at left...

Related Drugs and Biologics

1.	imatinib (Gleevec)
2.	Epidermal Growth Factor Receptor (EGF Receptor)
3.	gefitinib (Iressa)
4.	erlotinib (CP 358,774)
5.	sunitinib (Sutent)
6.	trastuzumab (Herceptin)
7.	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
8.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
9.	sorafenib (BAY 43-9006)
10.	gemcitabine

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Heterologous Transplantation (Xenotransplantation)
3.	Aftercare (After-Treatment)
4.	Therapeutics
5.	Transplantation (Transplant Recipients)